What You Can Expect in 2026?
Groundbreaking advancements in Treg space have provided the potential to redefine how we treat autoimmune, inflammatory and neurodegenerative diseases.
Yet, with this surging momentum, many questions in the community remain unanswered. The 8th Treg-Directed Therapy Summit unites the world’s leading minds to begin to answer the questions that remain in Treg biology understanding, novel therapeutic modalities, indication selection, therapeutic endpoints, patient selection, clinical trial design, clinical data and more.
At the only meeting dedicated exclusively to Treg therapies, engage with a 35% c-suite speaker faculty as they share unseen data, strategies and unmatched actionable insights to fast-track your therapeutic success.
Unmissable Event Highlights
Industry leader’s Insights
Hear from the Industry’s top innovators in Treg cell therapy, modulation and pharma S&E and BD as they share their thoughts on the industry defining developments, investment uptake the appetite for collaborative opportunities set to shape the future of the space
Rama Kataria, Associate Director, Business Development, Alexion Pharmaceuticals
Jonathan Zalevsky, Chief Research & Development Officer, Nektar Therapeutics
Jon Weiss, Head, Business Development, Cellenkos
Unravel the Mysteries of Treg Biology
With a full understanding of Treg biology still evading the industry, join leading academics and scientists sharing the latest on our understanding of Treg development, function, stability and more
Wanjun Chen, Senior Investigatory, NIH
Stephen Miller, Professor of Microbiology & Immunology, Northwestern University
Wei Hu, Assistant Professor, Yale University
Explore Neuroimmune Frontiers
Learn from pioneers breaking barriers in brain access and redefining what’s possible in treating neurodegenerative diseases
Scott Shandler, Founder & Chief Executive Officer, Longevity Biotech
Skin-Deep Immunity
Hear from the Industry’s top innovators in Treg cell therapy, modulation and pharma S&E and BD as they share their thoughts on the industry defining developments, investment uptake the appetite for collaborative opportunities set to shape the future of the space
Rama Kataria, Associate Director, Business Development, Alexion Pharmaceuticals
Jonathan Zalevsky, Chief Research & Development Officer, Nektar Therapeutics
Jon Weiss, Head, Business Development, Cellenkos
Unravel the Mysteries of Treg Biology
See how the next wave of Treg innovation and clinical validation is redefining transplant care
Roberto Gedaly, Professor of Transplant Surgery, University of Kentucky
Francesc Marti, Associate Professor, Surgery, University of Kentucky
Marc Martinez Llordela, Vice President Biology, Quell Therapeutics
Explore the Full Event Guide
- A Streamlined, Single-Track Agenda so You Can Catch Every Insightful Session Without Missing a Moment
- A Refreshed Treg Biology Focus Day
- 9 Hours of Dedicated Networking with the Global Treg Community
- C-Suite Led Panel Discussions
- New Data Presentations
- A 75% New Speaker Faculty
Attending Companies Include
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.